However, compared to the robust favorable effects of SGLT2 inhibitors on diabetes mellitus, heart failure, and chronic kidney disease, results of studies on their clinical impact on sudden cardiac death (SCD) have been inconsistent. This evidence concerns the gene SLC5A2 and diabetes mellitus.